SNSE

Faeth Therapeutics, Inc. (SNSE) | Rumor.io

Faeth Therapeutics

SNSE

Attention (50-day avg)0%

Attention rank (50-day avg)#4,898

Bullish sentiment (50-day avg)100%

Price to earnings ratio-1.67

Market capitalization37.6M

Earnings per share-142.7

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-21.1M

Social

What share of all stock conversation is about SNSE?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

May 15

$SNSE went public via reverse merger, but its business model is not similar to Cerebras.
Millennium Management bought 30,585 shares of $SNSE for $818,260 at $21.24 on March 26-30, 2026.
Millennium Management also bought $141,000 worth of $SNSE shares at $33.54 on April 7, 2026.

Generated by AI

Sentiment

Of the messages about SNSE that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	89.32% -6.69
Bearish	—	—	—	10.68% +6.69

Bullish· Feb 23

The acquisition announcement for SNSE stock led to a 200% price surge to a 21-month high.
SNSE's price has been steadily increasing, holding up well and creeping higher.
SNSE's price action is strong, with potential for significant further gains.

Bearish· Feb 18

The company has been massively diluted, with existing shareholders seeing their ownership percentage reduced to around 4-5% after a private placement.
The company has an unprofitable business model and has issued a large amount of new shares at a low conversion price, which could lead to a significant decline in the stock price.
The company's private placement at $13.85 is seen as a warning sign, with some investors predicting a hard dump in the stock price as the conversion price is significantly lower than the current market price.

Generated by AI

Topics

Of the messages about SNSE that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	26.57%
Analysts	—	—	0%	18.38%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	19.62%
Technical Analysis	—	—	0%	35.43%

Announcements· Feb 20

Sensei Biotherapeutics, Inc. ($SNSE) breaks through $29.59 resistance, surging 22.78% to $33.42 on high volume.
The company's acquisition of Faeth Therapeutics and $200M private placement provide a fundamental catalyst for growth, with a strong strategic move to expand the platform.
The stock's momentum is extreme, with a powerful shift confirmed by technical analysis, and a next technical target of $42.48.

Technical Analysis· Feb 20

$SNSE has a bullish bias with high volatility, a structural breakout from a prolonged base, and elevated RSI of 75-80.
Key levels for $SNSE are support at $25/$23 and resistance at $30/$32, with the potential for continuation toward $30-32 as long as $25 holds.
$SNSE has confirmed a technical breakout with a price increase of +22.78% on massive volume, fueled by a strategic acquisition and $200M financing, with momentum targeting a measured move of $43.45.

Generated by AI

Community

Of the messages about SNSE, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	24.19%
Newcomers	—	—	100%	75.81%

May 15

Sensei Biotherapeutics, Inc. ($SNSE) recently went public via reverse merger, a less common method of entering the market.
The company has seen significant insider buying, with Millennium Management LLC purchasing $818,260 worth of shares in March 2026.
There is a growing interest in Sensei Biotherapeutics, Inc. due to the availability of simplified explanations for the company's news and recent developments.

Generated by AI

AUSTIN, Texas, September 17, 2026--Faeth Therapeutics, Inc. (Nasdaq: FTH), a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways, today announced that Karen Vousden, Ph.D., has been appointed to its Board of Directors, effective September 11, 2026.

12d agoYahoo Finance

Faeth stock gets new Buy at Guggenheim (FTH:NASDAQ)

13d agoSeeking Alpha

Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results

BOSTON, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery...

1mo agoBarchart.com

Exclusive BAC Article: Faeth Therapeutics; Year-End 2026 PIKTOR Endometrial Cancer Data, Breast Cancer Interim Results 2027, Solid Tumor Expansions, And Catalysts (NASDAQ:FTH)

1mo agoSeeking Alpha

Faeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial Cancer

1mo agoYahoo Finance

Faeth Therapeutics Strengthens Executive Team with Senior Leadership Appointments

AUSTIN, Texas, August 14, 2026--Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced the appointments of Deepak Tiwari as Senior Vice President, Technical Operations, and Matt Biegler as Senior Vice President, Investor Relations, as the company prepares for upcoming PIKTOR clinical milestones.

1mo agoYahoo Finance

Also Discussed

Investors talking about SNSE also mention

#	Name	Attention
1	Brand Engagement Network Inc.BNAI	0%+0
2	MKDWELL Tech Inc.MKDW	0%+0
3	AMC Robotics CorporationAMCI	0%0
4	Beasley Broadcast Group IncBBGI	0%new
5	NFT Ltd. Class A Ordinary ShareMI	0%+0
6	Atif Holdings Ltd.ZBAI	0%0
7	Global Interactive Technologies, Inc.GITS	0%0
8	Mannatech Inc.MTEX	0%0
9	A SPAC III Acquisition Corp. Class A Ordinary SharesASPC	0%0
10	ARB IOT Group LimitedARBB	0%0

Faeth Therapeutics, Inc.

Healthcare
Biotechnology

Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on integrating tumor metabolism into modern oncology treatment. The company develops multi-node therapies that target the PAM (PI3K/AKT/mTOR) signaling pathway, one of the most frequently altered oncogenic pathways in cancer, with the aim of blocking cancer growth signals while also managing the nutrient supply that fuels tumors. Its lead program, PIKTOR, is an all-oral investigational combination designed to achieve deeper pathway suppression with improved tolerability by inhibiting multiple nodes simultaneously. Faeth Therapeutics leverages a data-driven discovery platform that links tumor genotypes with specific therapeutic regimens and precision metabolic interventions, including nutrition-based strategies, to modulate cancer metabolism. Headquartered in San Francisco, California, and operating as a biotechnology research company, Faeth Therapeutics plays a specialized role in the oncology market by advancing metabolism-focused treatments for solid tumors within the broader biopharmaceutical and cancer therapeutics ecosystem.

Website

Location

1405 Research Boulevard

Rockville, MD, 20850

United States

Social

What share of all stock conversation is about SNSE?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

May 15

$SNSE went public via reverse merger, but its business model is not similar to Cerebras.
Millennium Management bought 30,585 shares of $SNSE for $818,260 at $21.24 on March 26-30, 2026.
Millennium Management also bought $141,000 worth of $SNSE shares at $33.54 on April 7, 2026.

Generated by AI

Sentiment

Of the messages about SNSE that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	89.32% -6.69
Bearish	—	—	—	10.68% +6.69

Bullish· Feb 23

The acquisition announcement for SNSE stock led to a 200% price surge to a 21-month high.
SNSE's price has been steadily increasing, holding up well and creeping higher.
SNSE's price action is strong, with potential for significant further gains.

Bearish· Feb 18

The company has been massively diluted, with existing shareholders seeing their ownership percentage reduced to around 4-5% after a private placement.
The company has an unprofitable business model and has issued a large amount of new shares at a low conversion price, which could lead to a significant decline in the stock price.
The company's private placement at $13.85 is seen as a warning sign, with some investors predicting a hard dump in the stock price as the conversion price is significantly lower than the current market price.

Generated by AI

Topics

Of the messages about SNSE that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	26.57%
Analysts	—	—	0%	18.38%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	19.62%
Technical Analysis	—	—	0%	35.43%

Announcements· Feb 20

Sensei Biotherapeutics, Inc. ($SNSE) breaks through $29.59 resistance, surging 22.78% to $33.42 on high volume.
The company's acquisition of Faeth Therapeutics and $200M private placement provide a fundamental catalyst for growth, with a strong strategic move to expand the platform.
The stock's momentum is extreme, with a powerful shift confirmed by technical analysis, and a next technical target of $42.48.

Technical Analysis· Feb 20

$SNSE has a bullish bias with high volatility, a structural breakout from a prolonged base, and elevated RSI of 75-80.
Key levels for $SNSE are support at $25/$23 and resistance at $30/$32, with the potential for continuation toward $30-32 as long as $25 holds.
$SNSE has confirmed a technical breakout with a price increase of +22.78% on massive volume, fueled by a strategic acquisition and $200M financing, with momentum targeting a measured move of $43.45.

Generated by AI

Community

Of the messages about SNSE, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	24.19%
Newcomers	—	—	100%	75.81%

May 15

Sensei Biotherapeutics, Inc. ($SNSE) recently went public via reverse merger, a less common method of entering the market.
The company has seen significant insider buying, with Millennium Management LLC purchasing $818,260 worth of shares in March 2026.
There is a growing interest in Sensei Biotherapeutics, Inc. due to the availability of simplified explanations for the company's news and recent developments.

Generated by AI

Faeth Therapeutics

Social

May 15

Sentiment

Bullish· Feb 23

Bearish· Feb 18

Topics

Announcements· Feb 20

Technical Analysis· Feb 20

Community

May 15

News

Faeth Therapeutics Appoints Karen Vousden, Ph.D., to Board of Directors

Faeth stock gets new Buy at Guggenheim (FTH:NASDAQ)

Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results

Exclusive BAC Article: Faeth Therapeutics; Year-End 2026 PIKTOR Endometrial Cancer Data, Breast Cancer Interim Results 2027, Solid Tumor Expansions, And Catalysts (NASDAQ:FTH)

Faeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial Cancer

Faeth Therapeutics Strengthens Executive Team with Senior Leadership Appointments

Also Discussed

Faeth Therapeutics, Inc.

Company Information

Location

News

Faeth Therapeutics Appoints Karen Vousden, Ph.D., to Board of Directors

Faeth stock gets new Buy at Guggenheim (FTH:NASDAQ)

Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results

Exclusive BAC Article: Faeth Therapeutics; Year-End 2026 PIKTOR Endometrial Cancer Data, Breast Cancer Interim Results 2027, Solid Tumor Expansions, And Catalysts (NASDAQ:FTH)

Faeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial Cancer

Faeth Therapeutics Strengthens Executive Team with Senior Leadership Appointments

Also Discussed

Social

May 15

Sentiment

Bullish· Feb 23

Bearish· Feb 18

Topics

Announcements· Feb 20

Technical Analysis· Feb 20

Community

May 15